Our website lists jobs from 1152 biotech startups.
| Company (click to see more info) | Short description | Founded | Location | Clinical stage | Therapy area | Drug types | Drug notes | Funding | Investors |
|---|---|---|---|---|---|---|---|---|---|
| 1. 1910 Genetics | Computational chemistry platform to develop small molecule therapeutics | 2018 | Boston, MA | RD | Neurological conditions | NEU, INF, IMM, ONC, RAR, GEN | Undisclosed programs RD infectious diseases, immunology conditions, oncology, rare & genetic diseases | $22M A Mar 2021; $4.1M Seed | FoundersX Ventures, Y Combinator, Scientia Ventures, Emles Advisors, Tuck Lye Koh of Shunwei Capital, M12 |
| 2. 20n Bio | Computational Synthetic Biology | 2021 | Malvern, PA | $3.3M seed Dec 2021 | BlueRun Ventures China | ||||
| 3. 3DBio Therapeutics | Therapeutic-grade Bioprinting | 2014 | Long Island City, NY | $5.3M A Apr 2021 | |||||
| 4. 3T Biosciences | TCR Therapies | 2017 | South SF, CA | RD | Solid tumors | ONC, IMM, VAC, INF | Undisclosed programs RD autoimmune diseases, viral infections | $40M A Aug 2022; $12M seed Oct 2017 | Westlake Village BioPartners, Lightspeed Venture Partners |
| 5. 4D Molecular Therapeutics | Gene Therapy | 2013 | Emeryville, CA | Clin1/Clin2 | Fabry disease | GEN, OPH, RAR, LNG, GER, CVV | 4D-150 Clin1/Clin2 wet AMD, Clin0 DME; 4D-125 Clin1/Clin2 XLRP; 4D-110 Clin1/Clin2 choroideremia; 4D-710 Clin1/Clin2 cystic fibrosis, additional effort Clin0 cystic fibrosis; 4D-175 RD geographic atrophy; 4D-725 RD A1AT deficiency; undisclosed RD eye disease | $138M stock May 2023; $222M IPO Dec 2020; $75M Jun 2020; $90M B Sep 2018; $20M prior | |
| 6. 64x Bio | High throughput discovery and design of enhanced cell lines for next-generation biomanufacturing and therapeutics | 2018 | San Francisco, CA | $55M A Jan 2022 | |||||
| 7. 76Bio | Targeted Protein Degraders | 2020 | Boston, MA | RD | |||||
| 8. A-Alpha Bio | Yeast-based Drug Assay | 2017 | Seattle, WA | $22.4M A2 Jul 2023; $20M A Sep 2021; $2.8M seed Sep 2019; $225 NSF grant Jul 2018 | |||||
| 9. A2 Biotherapeutics | Immunotherapy | 2017 | Agoura Hills, CA | Clin1 | Multiple cancers | ONC | A2B694 Clin0 multiple cancers; 3 undisclosed programs RD undisclosed | $71.5M B Oct 2020; $57M A Nov 2019 | |
| 10. AAVogen | 2015 | Rockville, Maryland | <10M | ||||||
| 11. ACELYRIN | |||||||||
| 12. AI Proteins | |||||||||
| 13. AIRNA Bio | |||||||||
| 14. ALX Oncology | Immuno-oncology | 2015 | South SF, CA | Clin2 (fast track) | Head & neck cancer (partner: Merck) | ONC | Also different combo Clin2 (fast track) head & neck cancer (partner: MercK), Clin2 (fast track) gastric cancer (partner: Lilly), Clin1 urothelial cancer; 2 trials Clin1 breast cancer (one partnered: Zymeworks), Clin0 multiple myeloma; ALTA-002 Clin0 oncology | $185.7M IPO Jul 2020; $105M C Feb 2020; $36M A Mar 2015 | |
| 15. AN2 Therapeutics | Novel medicines targeting infectious diseases | 2019 | Menlo Park, CA | Clin1 | NTM lung disease | INF | Also 2 additional efforts Clin0/Clin1 NTM lung diseases, Clin0 melioidosis | $70M stock Aug 2023; $79.4M IPO Mar 2022; $80M B Jan 2022; $12M A Nov 2019 | |
| 16. AOA Dx | Cancer Diagnosis | 2020 | Boulder, CO | $7M Seed Sep 2022 | Avestria Ventures, AlleyCorp, The Helm, RH Capital, Olive Tree Capital, Tencent | ||||
| 17. ARTBIO | |||||||||
| 18. AUM BioTech | RNA-silencing Products | 2015 | Philadelphia, PA | ||||||
| 19. AVROBIO | Cellular & Gene Therapies | 2016 | Cambridge, MA | Clin1/Clin2 | Gaucher disease type 1 | RAR, GEN, PED | Also Clin0 Gaucher disease type 3; AVR-RD-04 Clin1/Clin2 cystinosis; AVR-RD-05 Clin0 Hunter syndrome; AVR-RD-03 Clin0 Pompe disease | $100M IPO Feb 2020 | |
| 20. Ab Studio | Antibody humanization and optimization service | 2017 | Hayward, CA | ||||||
| 21. Abalone Bio | Antibody Therapies | 2017 | Emeryville , CA | Clin0 | Diabetic peripheral neuropathic pain | PN, LNG, INF, HEP, GI, ONC, NPH, END, NWL | Undisclosed Clin0 liver fibrosis/NASH; undisclosed Clin0 lung conditions/influenza; undisclosed Clin0 IBD; 5 undisclosed programs RD immuno-oncology, polycystic kidney disease, obesity, diabetes | ||
| 22. Abata Therapeutics | Treg Cell Therapies | 2021 | Cambridge, MA | Clin0 | MS | IMM, NEU, END, MUS | Undisclosed programs RD diabetes (1), RD inclusion body myositis | $95M A Jun 2021 | |
| 23. Abeona Therapeutics | Therapies for Sanfilippo (SF) Syndrome Type A and Type B. | 2013 | Cleveland, OH | Clin3 (fast track) | Recessive dystrophic epidermolysis bullosa (ODD) | GEN, DRM, PED, RAR, OPH | AB0-504 RD/Clin0 Stargardt disease; ABO-503 RD/Clin0 x-linked retinoschisis; ABO-505 RD/Clin0 autosomal dominant optic atrophy; AIM Vectors RD undisclosed | $25M stock Jul 2023; $35M stock Nov 2022; $25M stock Apr 2022 | |
| 24. Abintus Bio | Gene Therapy | 2020 | San Diego, CA | Clin0 | Lymphomas | ONC, INF | 3 undisclosed programs RD oncology, infectious disease, undisclosed | ||
| 25. Abiosciences | |||||||||
| 26. Absci | |||||||||
| 27. Accelevir Diagnostics | |||||||||
| 28. Accent Therapeutics | |||||||||
| 29. Acepodia | |||||||||
| 30. Achieve Life Sciences | |||||||||
| 31. Acomhal Research | 2017 | Roanoke, Virginia | <10M | ||||||
| 32. Acrivon Therapeutics | |||||||||
| 33. Actym Therapeutics, Inc. | 2017 | Berkeley, California | 10 - 100M | ||||||
| 34. Acutis Diagnostics | |||||||||
| 35. Adaptive Phage Therapeutics | |||||||||
| 36. Adcentrx Therapeutics | |||||||||
| 37. Adicet Bio | |||||||||
| 38. Aditum Bio | |||||||||
| 39. Admera Health | |||||||||
| 40. Adverum Biotechnologies | |||||||||
| 41. Aeglea BioTherapeutics | |||||||||
| 42. Aether Bio | |||||||||
| 43. Affini-T Therapeutics | |||||||||
| 44. Affinia Therapeutics | |||||||||
| 45. Affinivax | |||||||||
| 46. AgBiome | |||||||||
| 47. Agastiya Biotech | 2019 | Temecula, California | not disclosed | ||||||
| 48. Agena Bioscience | |||||||||
| 49. AiViva Biopharma | 2016 | Newport Beach, California | not disclosed | ||||||
| 50. Ainnocence | 2021 | San Francisco, California | not disclosed |